Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

September 25, 2018

- Gaurav Shah, M.D., Chief Executive Officer, Invited as Panel Member at The Galien Forum USA 2018 -

NEW YORK--(BUSINESS WIRE)--Sep. 25, 2018-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a leading U.S.-based multi-platform gene therapy company, today announced that members of Rocket's executive team will participate in the following upcoming conferences:

- Cantor Fitzgerald Global Healthcare Conference on October 1, 2018, at 9:30 a.m. Eastern Time in New York, NY
- Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018, at 11:30 a.m. Eastern Time in New York, NY
- Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018, at 1:30 p.m. Eastern Time in New York, NY
- Chardan Genetic Medicines Conference on October 9, 2018, at 2:00 p.m. Eastern Time in New York, NY
- Gene Therapy Panel during The Galien Forum USA 2018 on October 25, 2018, at 2:40 p.m. Eastern Time in New York, NY

A live audio webcast of the Ladenburg presentation will be available on the Investors section of the company's website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket") is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket's multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180925005138/en/

Source: Rocket Pharmaceuticals, Inc.

Claudine Prowse, Ph.D.
SVP, Corporate Strategy and IRO
Rocket Pharma, Inc.
The Empire State Building, Suite 7530
New York, NY 10118
cp@rocketpharma.com
www.rocketpharma.com
investors@rocketpharma.com